Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.

PURPOSE Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of < 10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. PATIENTS AND METHODS The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. RESULTS Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. CONCLUSION This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.

[1]  Maximilian Diehn,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Archives of pathology & laboratory medicine.

[2]  B. Garcia,et al.  Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers , 2017, Science Translational Medicine.

[3]  C. Borrebaeck.  Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer , 2017, Nature Reviews Cancer.

[4]  Gun Ho Jang,et al.  A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns , 2016, Nature.

[5]  A. Carrato,et al.  Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Brentnall.  Progress in the Earlier Detection of Pancreatic Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Berlin,et al.  Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. , 2016, JAMA oncology.

[8]  Hua Gao,et al.  Whole-exome sequencing identifies variants in invasive pituitary adenomas , 2016, Oncology letters.

[9]  X. Wu,et al.  Systematic review and meta-analysis of minimally invasive versus open approach for pancreaticoduodenectomy , 2016, Surgical Endoscopy.

[10]  K. Hanada,et al.  Effective screening for early diagnosis of pancreatic cancer. , 2015, Best practice & research. Clinical gastroenterology.

[11]  D. Tuveson,et al.  Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus , 2015, Clinical Cancer Research.

[12]  David Moher,et al.  STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies , 2015, BMJ : British Medical Journal.

[13]  N. Malats,et al.  A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma , 2015, International journal of proteomics.

[14]  S. Duffy,et al.  Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma , 2015, Clinical Cancer Research.

[15]  Suresh T. Chari,et al.  Early Detection of Sporadic Pancreatic Cancer , 2015, Pancreas.

[16]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[17]  Yasuyuki Suzuki,et al.  Strategies for early detection of resectable pancreatic cancer. , 2014, World journal of gastroenterology.

[18]  Peter Kraft,et al.  Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development , 2014, Nature Medicine.

[19]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[20]  W. Greenhalf,et al.  Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease , 2014, Molecular Cancer.

[21]  L. Banks,et al.  Restoration of MAGI-1 Expression in Human Papillomavirus-Positive Tumor Cells Induces Cell Growth Arrest and Apoptosis , 2014, Journal of Virology.

[22]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[23]  S. Duan,et al.  Four Genetic Polymorphisms of Lymphotoxin-Alpha Gene and Cancer Risk: A Systematic Review and Meta-Analysis , 2013, PloS one.

[24]  C. Galli,et al.  CA 19-9: handle with care , 2013, Clinical chemistry and laboratory medicine.

[25]  S. Roberts,et al.  The PDZ protein discs‐large (DLG): the ‘Jekyll and Hyde’ of the epithelial polarity proteins , 2012, The FEBS journal.

[26]  R. Andersson,et al.  Serum proteome profiling of pancreatitis using recombinant antibody microarrays reveals disease‐associated biomarker signatures , 2012, Proteomics. Clinical applications.

[27]  C. Borrebaeck,et al.  Identification of serum biomarker signatures associated with pancreatic cancer. , 2012, Cancer research.

[28]  G. Petersen,et al.  New-onset diabetes in pancreatic cancer: a study in the primary care setting. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[29]  Carsten Peterson,et al.  Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases , 2011, Proceedings of the National Academy of Sciences.

[30]  William E Grizzle,et al.  Serum Biomarker Panels for the Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.

[31]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[32]  F. Romano,et al.  Prolonged Survival of a Patient Affected by Pancreatic Adenocarcinoma with Massive Lymphocyte and Dendritic Cell Infiltration after Interleukin-2 Immunotherapy. Report of a Case , 2008 .

[33]  F. Romano,et al.  Prolonged survival of a patient affected by pancreatic adenocarcinoma with massive lymphocyte and dendritic cell infiltration after interleukin-2 immunotherapy. Report of a case. , 2008, Tumori.

[34]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[35]  Joel G Fletcher,et al.  Resectability of Presymptomatic Pancreatic Cancer and Its Relationship to Onset of Diabetes: A Retrospective Review of CT Scans and Fasting Glucose Values Prior to Diagnosis , 2007, The American Journal of Gastroenterology.

[36]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Joaquin Casal,et al.  Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma , 2006, Anti-cancer drugs.

[38]  K. Yamao,et al.  Small carcinoma of the pancreas is curable: New computed tomography finding, pathological study and postoperative results from a single institute , 2005, Journal of gastroenterology and hepatology.

[39]  Mariza de Andrade,et al.  Probability of pancreatic cancer following diabetes: a population-based study. , 2005, Gastroenterology.

[40]  J G Fletcher,et al.  Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. , 2004, AJR. American journal of roentgenology.

[41]  F. Motoi,et al.  Pancreatic Cancer Registry in Japan: 20 Years of Experience , 2004, Pancreas.

[42]  J. Permert,et al.  The relationship between diabetes and pancreatic cancer , 2003, Molecular Cancer.

[43]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[44]  S. Mamidi,et al.  The complement system in cancer: Ambivalence between tumour destruction and promotion. , 2017, Immunobiology.

[45]  John D Lambris,et al.  The role of complement in tumor growth. , 2014, Advances in experimental medicine and biology.

[46]  Pikli Batabyal Mbbs,et al.  Association of Diabetes Mellitus and Pancreatic Adenocarcinoma: A Meta-Analysis of 88 Studies , 2014, Annals of Surgical Oncology.

[47]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[48]  Wolfgang Schima,et al.  Pancreatic adenocarcinoma , 2006, European Radiology.

[49]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.